Boehringer Ingelheim announces initiation of pivotal trial investigating volasertib* in patients with acute myeloid leukaemia
28 February 2013 | By Boehringer Ingelheim
Boehringer Ingelheim invests in rare diseases...
List view / Grid view
28 February 2013 | By Boehringer Ingelheim
Boehringer Ingelheim invests in rare diseases...
28 February 2013 | By Novartis
Novartis today announced that it has launched an effort to eliminate rheumatic heart disease in Zambia in collaboration with the Lusaka...
27 February 2013 | By Weber Shandwick
EURORDIS announced that Celgene Corporation has been awarded the prestigious EURORDIS Company Award for excellence in the field of rare diseases...
27 February 2013 | By Genzyme
Sanofi and its subsidiary Genzyme announced today that Genzyme has received a Company Award from EURORDIS...
There are many Limulus Amebocyte Lysate (LAL) methods commercially available today. Hence, Lonza is hosting a free, 60-minute webinar entitled "Endotoxin Detection – Which Method Is Best for Me" at two different dates and times.
26 February 2013 | By The New York Academy of Sciences
The Academy awarded a challenge grant...
26 February 2013 | By Roche
Independent body to grant access to patient-level data for scientific review...
26 February 2013 | By AstraZeneca
AstraZeneca announced high-level results from KODIAC-08...
24 February 2013 | By Novartis
Late-breaking results from ASTERIA II...
23 February 2013 | By Boehringer Ingelheim
New Phase III data presented...
22 February 2013 | By Sanofi
The EMA recommended market approval for Sanofi Pasteur’s 6-in-1 pediatric vaccine...
22 February 2013 | By Roche
New personalised medicine helped people in Phase III study live longer, compared to standard treatment...
21 February 2013 | By kdm communications
“We have adopted a unique approach to functional proteomics..."
21 February 2013 | By Biosector 2
ARIAD announced the appointment of Jonathan E. Dickinson...
21 February 2013 | By Boehringer Ingelheim
Findings from two trials...